Transplantation of allogeneic hematopoietic stem cells: an emerging treatment modality for solid tumors
Taner Demirer, Lisbeth Barkholt, Didier Blaise, Paolo Pedrazzoli, Massimo Aglietta, Angelo Michele Carella, Jacques-Olivier Bay, Fikret Arpaci, Giovanni Rosti, Gunhan Gurman, Dietger Niederwieser and Marco Bregni* on behalf of the EBMT Solid Tumors Working Party
Correspondence *Department of Oncology, Scientific Institute San Raffaele, Via Olgettina 60, I–20132 Milano, Italy
Email marco.bregni@hsr.it
Allogeneic non-myeloablative stem-cell transplantation is feasible for patients with various refractory and advanced solid tumors. Current data suggest that the graft-versus-tumor effect associated with this approach might prolong survival of some patients with metastatic solid tumors. The authors discuss the latest results from the literature and recent data from the European Bone Marrow Transplantation Solid Tumors Working Party.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$32 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.